These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29074595)

  • 1. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
    Harrison CN; Mead AJ; Panchal A; Fox S; Yap C; Gbandi E; Houlton A; Alimam S; Ewing J; Wood M; Chen F; Coppell J; Panoskaltsis N; Knapper S; Ali S; Hamblin A; Scherber R; Dueck AC; Cross NCP; Mesa R; McMullin MF
    Blood; 2017 Oct; 130(17):1889-1897. PubMed ID: 29074595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
    Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
    Harrison CN; Nangalia J; Boucher R; Jackson A; Yap C; O'Sullivan J; Fox S; Ailts I; Dueck AC; Geyer HL; Mesa RA; Dunn WG; Nadezhdin E; Curto-Garcia N; Green A; Wilkins B; Coppell J; Laurie J; Garg M; Ewing J; Knapper S; Crowe J; Chen F; Koutsavlis I; Godfrey A; Arami S; Drummond M; Byrne J; Clark F; Mead-Harvey C; Baxter EJ; McMullin MF; Mead AJ
    J Clin Oncol; 2023 Jul; 41(19):3534-3544. PubMed ID: 37126762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
    Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
    Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
    Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
    Mesa R; Vannucchi AM; Yacoub A; Zachee P; Garg M; Lyons R; Koschmieder S; Rinaldi C; Byrne J; Hasan Y; Passamonti F; Verstovsek S; Hunter D; Jones MM; Zhen H; Habr D; Martino B
    Br J Haematol; 2017 Jan; 176(1):76-85. PubMed ID: 27858987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
    O'Sullivan JM; Hamblin A; Yap C; Fox S; Boucher R; Panchal A; Alimam S; Dreau H; Howard K; Ware P; Cross NCP; McMullin MF; Harrison CN; Mead AJ
    Blood; 2019 Dec; 134(23):2107-2111. PubMed ID: 31578205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
    Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M
    Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
    Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
    Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
    Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
    Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
    Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
    Verstovsek S; Vannucchi AM; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Kirito K; Besses C; Hino M; Moiraghi B; Miller CB; Cazzola M; Rosti V; Blau I; Mesa R; Jones MM; Zhen H; Li J; Francillard N; Habr D; Kiladjian JJ
    Haematologica; 2016 Jul; 101(7):821-9. PubMed ID: 27102499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
    Tremblay D; Ronner L; Podoltsev N; Gotlib J; Heaney M; Kuykendall A; O'Connell C; Shammo JM; Fleischman A; Mesa R; Yacoub A; Hoffman R; Moshier E; Zubizarreta N; Mascarenhas J
    Leuk Res; 2021 Oct; 109():106629. PubMed ID: 34082375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
    Griesshammer M; Saydam G; Palandri F; Benevolo G; Egyed M; Callum J; Devos T; Sivgin S; Guglielmelli P; Bensasson C; Khan M; Ronco JP; Passamonti F
    Ann Hematol; 2018 Sep; 97(9):1591-1600. PubMed ID: 29804268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
    Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
    Chang L; Duan MH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.